HOME >> BIOLOGY >> NEWS
Allergy And Asthma-Exaceberating Mites, Molds And Pollens On The Rise Due To El Niño . . . La Niña

LOS ANGELES (July 29, 1998) -- El Niño has brought more than rainy weather to Southern California this year. According to two specialists at Cedars-Sinai Medical Center, allergy and asthma sufferers can expect more frequent and more severe attacks this year. Moreover, because of a related weather condition known as La Niña, the projection for next year is also for increased and more severe attacks. La Niña is a weather pattern of hot, dry winds which follows El Niño. While El Niño's wet weather causes a proliferation of plant growth and pollens, these dry and float to the desert floor as the rains decrease. However, as the La Niña pattern moves into place, the hot, dry winds kick up the pollens once again, renewing allergy and asthma attacks.

"This year, conditions in Southern California are worse for allergy and asthma sufferers because of the high levels of humidity that have resulted in excessive pollens, molds, ticks and mites," says Zab Mohsenifar, M.D., Chair of the Pulmonary and Critical Care Department at Cedars-Sinai Medical Center. Robert Eitches, M.D., an attending physician in the medical center's departments of internal medicine and pediatrics, agrees. The very rainy weather has resulted in increased mold growth, both indoors and outdoors, and has also resulted in rapid plant growth which leads to elevated pollen counts. In addition, when the weather is bad, people tend to stay indoors more, and the close proximity often results in viral infections which can lead to asthma attacks.

If that weren't enough, the high humidity has also provided an ideal environment for cockroaches and microscopic dust mites -- the leading cause of asthma. According to a recent survey, asthma rates are highest in the inner cities, especially among African-Americans and Hispanic Americans, and especially among youngsters who may be allergic to the proteins found in the saliva, droppings and remains of cockroaches. Asthma
'"/>

Contact: Sandra Van or Roberta Nichols
sandy@vancommunications.com
Cedars-Sinai Medical Center
29-Jul-1998


Page: 1 2 3 4

Related biology news :

1. Key Asthma And Allergy Molecule Pictured
2. Photocatalytic Air Cleaning System Promises To Help Allergy Sufferers
3. Researcher Finds Worlds Most Diverse Home Of Slime Molds
4. El Niños dramatic impact on ocean biology and carbon dioxide captured by unique monitoring system
5. El Niño triggers tropical forest reproduction
6. Study indicates Indian Ocean monsoon similar to El Niño phenomenon in Pacific
7. Forecasting The El Niño-Driven Ebb And Flow Of A Rogue Mosquito
8. Remote Cloud Observatory Tracks El Niño Changes

Post Your Comments:
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: